1. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, Ladas SD, Sfikakis PP. Arthritis Res Ther. 2016 Sep 1; 18:195. { Impact Factor : 4.269}
  2. Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.Karamanolis GP, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD. United European Gastroenterol J. 2015 Jun;3(3):266-71. {Impact Factor 3.477}
  3. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. Ann Gastroenterol. 2015 Jan-Mar;28(1):109-117. {Impact factor = 1.25}
  4. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. Karlafti EF, Hatzitolios AI, Karlaftis AF, Baltatzi MS, Koliakos GG, Savopoulos CG. J Pharm Bioallied Sci. 2013 Oct;5(4):253-6. {Impact factor = 1.31}
  5. Clinical characteristics in patients with non-cardiac chest pain could favor gastroesophageal reflux disease diagnosis. Karlaftis A, Karamanolis G, Triantafyllou K, Polymeros D, Gaglia A, Triantafyllou M, Papanikolaou IS, Ladas SD. Ann Gastroenterol. 2013; 26(4):314-318. {Impact factor = 1.25}

Επιστροφή στο βιογραφικό